Clovis Oncology (DB:C6O) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

C6O Aktienübersicht

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Mehr Details

C6O grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

Die Erträge sind in den letzten 5 Jahren um 5.6% pro Jahr gestiegen.

Risikoanalyse

Stark schwankender Aktienkurs in den letzten 3 Monaten

Negatives Eigenkapital

Hat keine nennenswerte Marktkapitalisierung (€2M)

Die letzten Finanzberichte sind mehr als 6 Monate alt

Clovis Oncology, Inc. Wettbewerber

Epigenomics

XTRA:ECX

€616.0k

Paion

XTRA:PA8

€2.6m

co.don

XTRA:CNW

€6.5m

Sangui Biotech International

HMSE:SBH

€419.8k

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Clovis Oncology
Historische Aktienkurse
Aktueller Aktienkurs	€0.023
52-Wochen-Hoch	€2.46
52-Wochen-Tief	€0.01
Beta	0.66
11 Monat Veränderung	130.00%
3 Monate Veränderung	-16.06%
1 Jahr Veränderung	-99.07%
33 Jahre Veränderung	-99.60%
5 Jahre Veränderung	-99.94%
Veränderung seit IPO	-99.86%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	C6O	DE Biotechs	DE Markt
7D	53.3%	0.8%	0.8%
1Y	-99.1%	-18.3%	8.6%

Rendite im Vergleich zur Industrie: C6O unter dem Niveau der Branche German Biotechs , die im vergangenen Jahr eine Rendite von -18.3% erzielte.

Rendite vs. Markt: C6O hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is C6O's price volatile compared to industry and market?
C6O volatility
C6O Average Weekly Movement	104.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiler Aktienkurs: C6ODer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: C6ODie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 91% auf 105% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Clovis Oncology im Vergleich zum Marktanteil des Unternehmens?
C6O grundlegende Statistiken
Marktanteil	€2.18m
Gewinn(TTM)	-€226.19m
Umsatz(TTM)	€119.44m

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist C6O zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
C6O Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$133.02m
Kosten der Einnahmen	US$31.59m
Bruttogewinn	US$101.43m
Sonstige Ausgaben	US$353.33m
Umsatz	-US$251.91m

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.73
Bruttomarge	76.25%
Nettogewinnspanne	-189.37%
Schulden/Eigenkapital-Verhältnis	-158.0%

Wie hat sich C6O auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

C6O Aktienübersicht

Belohnungen

Risikoanalyse

Clovis Oncology, Inc. Wettbewerber

XTRA:ECX

€616.0k

XTRA:PA8

€2.6m

XTRA:CNW

€6.5m

HMSE:SBH

€419.8k

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue beats expectations

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €7.51

New 90-day high: €4.99

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.84

Clovis Oncology, Inc. to Report Q1, 2020 Results on May 05, 2020

Clovis Oncology, Inc. Presents Highlight Breadth and Potential of Clovis Oncology Products and Pipeline At ESMO Virtual Congress 2020

First half earnings released

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Clovis Oncology, Inc.'s Grundlagenzusammenfassung

0.0x

0.0x

Erträge &amp; Einnahmen

Erträge & Einnahmen